Tyrosinase peptide–HLA class II complex (TYR-HLA-II)

The Tyrosinase peptide–HLA class II complex is a molecular assembly consisting of a peptide fragment derived from the tyrosinase enzyme bound to a Human Leukocyte Antigen (HLA) class II molecule, such as HLA-DR [PMID: 15155838]. Tyrosinase is the rate-limiting enzyme in melanin biosynthesis and is highly expressed in melanocytes and melanoma cells [UniProt: P14679]. In the immune system, these complexes are presented on the surface of cells to be recognized by the T-cell receptors (TCRs) of CD4+ T helper cells [PMID: 9151705]. This recognition is vital for the induction of a robust anti-tumor immune response, as CD4+ T cells coordinate the activity of other immune effectors like CD8+ T cells and B cells [PMID: 22566551]. In clinical oncology, this complex serves as a target for cancer vaccines and TCR-based immunotherapies aimed at treating metastatic melanoma [PMID: 11015558]. However, because tyrosinase is a self-antigen, therapeutic targeting can lead to autoimmune destruction of healthy melanocytes, resulting in vitiligo [PMID: 10426999].

Other names

Tyrosinase-derived peptide-MHC class II complexTYR-MHC-II complexTyrosinase-HLA-DR complexTyrosinase-HLA-DQ complexTyrosinase-HLA-DP complex

Induction of CD4+ T-cell mediated anti-tumor immunity through the recognition of tyrosinase epitopes presented on HLA class II molecules [PMID: 15155838].